Deutsche Bank AG Purchases 19,308 Shares of Tandem Diabetes Care, Inc. (NASDAQ:TNDM)

Deutsche Bank AG boosted its position in shares of Tandem Diabetes Care, Inc. (NASDAQ:TNDM) by 45.5% during the 4th quarter, according to its most recent 13F filing with the SEC. The fund owned 61,771 shares of the medical device company’s stock after purchasing an additional 19,308 shares during the quarter. Deutsche Bank AG owned about 0.09% of Tandem Diabetes Care worth $2,225,000 at the end of the most recent reporting period.

Other institutional investors and hedge funds have also bought and sold shares of the company. Arizona State Retirement System lifted its stake in shares of Tandem Diabetes Care by 1.9% in the fourth quarter. Arizona State Retirement System now owns 18,961 shares of the medical device company’s stock worth $683,000 after buying an additional 362 shares in the last quarter. Bank of Montreal Can increased its position in shares of Tandem Diabetes Care by 4.3% during the fourth quarter. Bank of Montreal Can now owns 10,004 shares of the medical device company’s stock valued at $360,000 after acquiring an additional 409 shares in the last quarter. Summit Investment Advisors Inc. raised its holdings in Tandem Diabetes Care by 8.3% in the 4th quarter. Summit Investment Advisors Inc. now owns 6,870 shares of the medical device company’s stock worth $247,000 after acquiring an additional 525 shares during the last quarter. Assetmark Inc. raised its holdings in Tandem Diabetes Care by 77.5% in the 4th quarter. Assetmark Inc. now owns 1,225 shares of the medical device company’s stock worth $44,000 after acquiring an additional 535 shares during the last quarter. Finally, AlphaQuest LLC lifted its position in Tandem Diabetes Care by 138.7% in the 4th quarter. AlphaQuest LLC now owns 931 shares of the medical device company’s stock valued at $34,000 after acquiring an additional 541 shares in the last quarter.

Insider Buying and Selling

In related news, COO Jean-Claude Kyrillos bought 10,538 shares of the business’s stock in a transaction that occurred on Friday, March 7th. The stock was bought at an average cost of $18.12 per share, with a total value of $190,948.56. Following the completion of the purchase, the chief operating officer now owns 10,538 shares of the company’s stock, valued at approximately $190,948.56. The trade was a ∞ increase in their position. The acquisition was disclosed in a document filed with the SEC, which is available through this hyperlink. 1.90% of the stock is owned by insiders.

Analysts Set New Price Targets

Several brokerages have commented on TNDM. Stifel Nicolaus cut their target price on Tandem Diabetes Care from $60.00 to $31.00 and set a “buy” rating on the stock in a research note on Thursday, May 1st. Mizuho assumed coverage on Tandem Diabetes Care in a report on Thursday, April 10th. They set a “neutral” rating and a $20.00 price target on the stock. Sanford C. Bernstein downgraded Tandem Diabetes Care from an “outperform” rating to a “market perform” rating and reduced their price objective for the stock from $35.00 to $25.00 in a report on Friday, February 28th. Robert W. Baird decreased their target price on Tandem Diabetes Care from $33.00 to $24.00 and set a “neutral” rating for the company in a research report on Thursday, May 1st. Finally, Morgan Stanley cut shares of Tandem Diabetes Care from an “overweight” rating to an “equal weight” rating and lowered their target price for the company from $45.00 to $22.00 in a research note on Wednesday, March 5th. Eight investment analysts have rated the stock with a hold rating and eight have given a buy rating to the stock. According to MarketBeat.com, the company currently has an average rating of “Moderate Buy” and an average price target of $37.47.

Tandem Diabetes Care Trading Down 4.7%

Shares of Tandem Diabetes Care stock opened at $20.64 on Friday. The company has a market capitalization of $1.37 billion, a P/E ratio of -10.69 and a beta of 1.47. The company has a debt-to-equity ratio of 1.29, a quick ratio of 2.32 and a current ratio of 2.90. The company has a fifty day moving average of $19.38 and a 200 day moving average of $27.60. Tandem Diabetes Care, Inc. has a fifty-two week low of $15.75 and a fifty-two week high of $53.69.

Tandem Diabetes Care (NASDAQ:TNDM) last posted its quarterly earnings results on Wednesday, April 30th. The medical device company reported ($0.67) EPS for the quarter, missing analysts’ consensus estimates of ($0.60) by ($0.07). The business had revenue of $234.42 million for the quarter, compared to the consensus estimate of $220.19 million. Tandem Diabetes Care had a negative net margin of 14.84% and a negative return on equity of 44.19%. Tandem Diabetes Care’s revenue was up 22.3% compared to the same quarter last year. During the same period in the prior year, the business earned ($0.65) earnings per share. On average, sell-side analysts anticipate that Tandem Diabetes Care, Inc. will post -1.68 earnings per share for the current fiscal year.

About Tandem Diabetes Care

Tandem Diabetes Care, Inc, a medical device company, designs, develops, and commercializes technology solutions for people living with diabetes in the United States and internationally. The company's flagship product is the t:slim X2 insulin delivery system, a pump platform for managing insulin delivery and display continuous glucose monitoring sensor information directly on the pump home screen; and Tandem Mobi insulin pump, an automated insulin delivery system.